This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tafamidis meglumine oral


Oral formulations of tafamidis meglumine.

Drugs List

  • tafamidis meglumine 20mg capsules
  • VYNDAQEL 20mg capsules
  • Therapeutic Indications


    Treatment of TTR-FAP in adults with stage 1 symptomatic polyneuropathy

    Treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment.


    Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.


    The recommended dose is 20mg of tafamidis meglumine once daily.

    Additional Dosage Information

    If vomiting occurs after dosing and the capsule is identified and intact, then an additional dose should be administered. If no capsule is identified, then no additional dose is necessary. Resume with next day dosing as usual.


    Children under 18 years
    Hereditary fructose intolerance
    Liver transplant

    Precautions and Warnings

    Females of childbearing potential
    Renal impairment - creatinine clearance below or equal to 30ml/minute
    Severe hepatic impairment

    Treatment to be initiated and supervised by a specialist
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    May affect results of some laboratory tests
    Discontinue if patient undergoes liver transplant
    Female: Contraception required during and for 1 month after treatment

    Patients should be monitored continually to assess the need for other therapy, including the need for liver transplantation.

    Pregnancy and Lactation


    Tafamidis meglumine is contraindicated during pregnancy.

    The manufacturer does not recommend using tafamidis meglumine during pregnancy and in women of childbearing potential not using contraception. Animal studies have shown developmental toxicity. Human data is limited and as such a potential risk cannot be ruled out.


    Tafamidis meglumine is contraindicated during breastfeeding.

    The manufacturer does not recommend breastfeeding whilst taking tafamidis meglumine. Animal studies indicate tafamidis is expressed in the breast milk, but the quantity is unknown.

    Side Effects

    Upper abdominal pain
    Urinary tract infections
    Vulvovaginal infections

    Effects on Laboratory Tests

    A decrease in total thyroxine with no accompanying change to free thyroxine (T4) or thyroid stimulating hormone (TSH) may occur during treatment with tafamidis meglumine.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: September 2020

    Reference Sources

    Summary of Product Characteristics: Vyndaqel 20mg soft capsules. Pfizer Ltd. Revised February 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.